卵巢癌患者外周血sHLA-G表达水平及诊断价值研究  

The Plasma Level of sHLA-G in Patients with Ovarian Cancer and Its Clinical Diagnostic Value

作　　者：李施泉[1] 赵枰[1] 陈彤[1] LI Shiquan;ZHAO Ping;CHEN Tong(Department of Clinical Laboratory,Nantong First People′s Hospital,Nantong 226001,China)

机构地区：[1]南通市第一人民医院检验科,江苏南通226001

出　　处：《标记免疫分析与临床》2020年第6期1053-1055,1082,共4页Labeled Immunoassays and Clinical Medicine

基　　金：南通市卫生局青年基金资助项目(编号:WKZL2018021)。

摘　　要：目的探讨卵巢癌患者血浆可溶性HLA-G(sHLA-G)的表达水平和用于卵巢癌诊断的临床价值。方法选取2016年1月至2019年10月期间收治的经手术病理证实的42例卵巢癌患者为卵巢癌组,同期收治的30例良性卵巢肿瘤患者为卵巢良性肿瘤组,同期体检的30例健康妇女为健康对照组,应用酶联免疫吸附试验检测血浆sHLA-G水平,通过ROC曲线分析sHLA-G水平是否为卵巢癌的有效诊断标志物。结果卵巢癌患者血浆sHLA-G分泌水平(106.1±45.6U/mL)显著高于良性卵巢肿瘤患者(60.1±24.4U/mL)和健康对照者(48.9±12.1U/mL)(F=16.463,P<0.01)。ROC曲线分析结果表明,sHLA-G的诊断价值优于HE4和CA125。sHLA-G水平的ROC曲线下面积(AUC)为0.829,最佳诊断分界点为63.45U/mL,灵敏度达78.6%,特异性达75.0%。单独检测sHLA-G的灵敏度(78.6%)较高,单独检测CA125的特异性(90.0%)较高,联合sHLA-G和CA125的AUC为0.848(95%CI:0.769~0.926),联合检测的诊断价值优于单独检测。结论卵巢癌患者外周血sHLA-G水平显著增加并可能是卵巢癌的有效诊断标志物。sHLA-G联合HE4和CA125检测可提高对卵巢癌的诊断效能。Objective To explore the soluble form of HLA-G(sHLA-G)level in plasma and its clinical diagnostic value in patients with ovarian cancer.Methods 42 patients with ovarian cancer confirmed by pathology who admitted from January,2016 to October,2019 were enrolled as the ovarian cancer observation group,and 30 patients with benign ovarian tumors admitted during the same period were selected as the ovarian benign tumor group,while 30 healthy women for the physical examination during the same period were selected as the healthy controls group.ELISA were used to detect the concentration of sHLA-G in plasma samples.The feasibility of using sHLA-G as a potential biomarker for patients with ovarian cancer was assessed by using receiver operating characteristic(ROC)curve analysis.Results The concentrations of sHLA-G in plasma samples collected from patients with ovarian cancer(106.1±45.6U/mL)were significantly higher than those in patients with benign ovarian tumors(60.1±24.4U/mL)and healthy controls[(48.9±12.1)U/mL](F=16.463,P<0.01).ROC curve analysis showed that in terms of ovarian cancer diagnosis,the area under ROC curve(AUC),cutoff value,sensitivity and specificity for sHLA-G in plasma were 0.829,63.45U/mL,78.6%and 75.0%,respectively,which indicated a better performance for sHLA-G than HE4 and CA125 in differentiating ovarian cancer.The sensitivity of single detection of sHLA-G(78.6%)was higher,while the specificity of single detection of CA125(90.0%)was higher,and the AUC of sHLA-G and CA125 in combination diagnosis was 0.848(95%CI:0.769-0.926),suggesting that the diagnostic value of combined detection was higher than that of single detection.Conclusion The level of sHLA-G in plasma increases dramatically in patients with ovarian cancer,which suggests that sHLA-G could be used as a potential biomarker for the diagnosis of ovarian cancer.The combination diagnosis of sHLA-G with HE4 and CA125 can further enhance diagnostic efficacy for ovarian cancer.

关 键 词：卵巢肿瘤 可溶性人类白细胞抗原G 联合检测 

分 类 号：R737.71[医药卫生—肿瘤]